Carmustine 100mg Recall EL(26)A/05: Accord Healthcare Out-of-Specification Batch

What Has Been Recalled and Why

Accord Healthcare Ltd has issued a Class 2 medicines recall for a single batch of Carmustine 100mg Powder and Solvent for Concentrate for Solution for Infusion. The recall reference is EL(26)A/05. The reason given by the MHRA is an out-of-specification test result for the affected batch.

An out-of-specification result means that the batch has failed one or more of the quality tests required by its marketing authorisation. For a chemotherapy agent such as carmustine, the nature of the specification failure matters clinically. If the failure relates to potency, a patient could receive a subtherapeutic or supra-therapeutic dose. If it relates to sterility or particulate contamination, the risk of direct harm from administration is more immediate. The MHRA's Class 2 designation indicates a potential for harm, though the probability of a serious adverse outcome is considered remote.

Why Carmustine Supply Disruption Matters

Carmustine, also known as BCNU (bis-chloroethylnitrosourea), is an alkylating chemotherapy agent used predominantly in the treatment of brain tumours, including glioblastoma multiforme and anaplastic astrocytoma. It is also used in certain lymphoma regimens. It is not a widely manufactured medicine, and the global supply base is limited to a small number of producers.

For oncology centres managing patients on carmustine-containing regimens, a batch recall represents more than a paperwork exercise. If the recalled batch was the centre's primary or only stock, finding a replacement within the treatment schedule can be genuinely challenging. Carmustine treatment delays can have clinical consequences in fast-growing tumour types where treatment timing is important.

Carmustine has historically appeared on medicine shortage lists in several markets. The recall of a batch, even a single batch, serves as a reminder that specialist oncology medicines require contingency planning and access to alternative supply channels.

Steps for Oncology Pharmacy Teams

1. Identify whether you hold the recalled batch. Cross-reference your stock against the batch number specified in the EL(26)A/05 recall notice from Accord Healthcare.
2. Quarantine affected stock immediately. If you hold the recalled batch, remove it from active stock and place it in a clearly labelled quarantine area.
3. Assess your remaining carmustine supply. Determine whether unaffected stock is sufficient to cover ongoing treatment schedules.
4. Alert your oncology clinical team. If supply is tight, clinical teams need to know so they can plan around any potential shortage.
5. Follow Accord Healthcare's return instructions for the recalled batch and document the action taken.

Sourcing Alternative Carmustine

Carmustine is produced by manufacturers in several markets and can be sourced through an MHRA-licensed wholesale dealer under the unlicensed medicines framework when a licensed UK product is unavailable or has been recalled. The unlicensed import route requires appropriate prescriber documentation and supplier quality assurance, both of which Euro Biom manages as part of its standard operating procedures.

Euro Biom is an MHRA WDA-licensed wholesale exporter operating in specialist and shortage medicine supply. We have established supply relationships across multiple pharmaceutical markets and can assist oncology pharmacy procurement teams who need access to carmustine outside of the standard UK supply chain.